Illumina Sues Oxford Nanopore for Patent Infringement
News Feb 24, 2016
The lawsuits were filed concurrently with the U.S. International Trade Commission and in the U.S. District Court for the Southern District of California. Illumina is seeking all available remedies.
The lawsuits are based on U.S. Patent Nos. 8,673,550 and 9,170,230, which are entitled “MSP NANOPORES AND RELATED METHODS.” Illumina has exclusively licensed the patents in the field of nucleic acid sequencing from the UAB Research Foundation and the University of Washington. The lawsuits focus on ONT’s MinION and PromethION devices.
Illumina has made substantial investments to obtain licenses and develop the nanopore sequencing technology invented by researchers at the University of Alabama at Birmingham and University of Washington. Illumina filed the lawsuits to protect its investment and patent rights in this technology.
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.